Why the study?
Does active antihypertensive treatment reduce mortality and cardiovascular events in older adults with isolated systolic hypertension based on the extent of peripheral atherosclerosis?
Population
190 older adults with isolated systolic hypertension from the Pittsburgh center of the SHEP trial, evaluated…
Comparison
Active antihypertensive treatment vs Placebo
Design
Cohort, Randomly assigned (in the parent SHEP trial)
Follow-up
4 years
Authors
Loading...
Supports atherosclerosis-based stratification of CV risk and absolute antihypertensive benefit in isolated systolic hypertension; extends SHEP but remains hypothesis-generating.
Does active antihypertensive treatment reduce mortality and cardiovascular events in older adults with isolated systolic hypertension based on the extent of peripheral atherosclerosis?
In older adults with isolated systolic hypertension, the presence of peripheral atherosclerosis strongly predicts cardiovascular events, and these patients derive the greatest absolute benefit from antihypertensive therapy.
Sutton‐Tyrrell et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: